Acasti Pharma (NASDAQ:ACST) Stock, Quote.Headers.trade-ideas

Acasti Pharma

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACST

AGFY

AKTS

ARAV

ATAK

CANO

CELU

CURO

CUTR

CVKD

DADA

EHTH

LANV

LICY

LUXH

LXEO

Airspan Networks Holdings Inc. Common Stock

MIMO

MMAT

MRAI

MRSN

NCAC

NUKK

NVVE

PCSA

PHUN

PLUG

PRQR

RAMP

ROMA

SAVE

SIFY

ZCAR

ZVSA

Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results.

Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the consensus of $1.532 billion. Adjusted EPS of 25 cents topped the street view of 23 cents.

Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

ACON

ADPT

AFIB

AKLI

AVTX

BCAN

BFRG

BPTS

BSFC

DTCK

EBIX

FAZE

FEMY

ICPT

IFBD

IMVT

LIFW

MKUL

MLGO

NEWP

NHWK

NVOS

PGEN

PLAG

PLRX

RDZN

RNAZ

ROIV

SLNO

SPGC

SPRY

THAR

TROO

UNFI

VERA

VERV

Gainers


	Soleno Therapeutics, Inc.  (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome.


Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Acasti Pharma Inc (NASDAQ: ACST) shares are trading higher by 34.3% to $2.35 Tuesday morning after the company announced $7.5 million in private placement equity financing.

Why Acasti Pharma (ACST) Stock Is Exploding Higher

Acasti Pharma, Inc. - Class A Common Stock

Acasti Pharma Inc

Earnings

Acasti Pharma Q1 2025 EPS $(0.24) vs $(0.54) YoY

Biotech

General

Acasti Reaches 50% Enrollment In Pivotal Phase 3 STRIVE-ON Safety Trial

Acasti Pharma FY24 Revenue $(1.35) Up From $(5.71) YoY

Acasti Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACST#NASDAQ">ACST</a>) reported quarterly losses of $(0.21) per share. This is a 59.62 percent increase over losses of $(0.52) per share from the same period last year.

Acasti Pharma Q3 EPS $(0.21) Up From $(0.52) YoY

Craig-Hallum analyst Chase Knickerbocker initiates coverage on Acasti Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACST#NASDAQ">ACST</a>) with a Buy rating and announces Price Target of $6.

Price Target

Initiation

Analyst Ratings

Craig-Hallum Initiates Coverage On Acasti Pharma with Buy Rating, Announces Price Target of $6

The poster, Safety and Tolerability of Intravenous Versus Enteral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage, will be presented Thursday February 8th during the Ongoing Clinical Trials session of the conference.
The STRIVE-ON trial is a prospective, open-label, randomized (1:1 ratio), parallel group trial of GTX-104 compared with oral nimodipine, in patients hospitalized for aSAH. Key trial design features include:
<ul>
<li>Approximately 100 patients are expected to be enrolled at an estimated 25 hospitals in the U.S.</li>
<li>The primary endpoint is safety and will be measured as comparative adverse events, including hypotension, between the two groups.</li>
<li>GTX-104 will be administered as a continuous IV infusion of 0.15 mg/hour, and a 30-minute IV bolus of 4 mg every 4 hours. Oral nimodipine will be administered as 60 mg (two 30 mg capsules) every 4 hours.
<ul>
<li>Both groups will receive their assigned GTX-104 or oral nimodipine for up to 21 consecutive days and will be evaluated from commencement of patient treatment through a 90-day follow-up period.</li>
</ul>
</li>
</ul>

Acasti Announces Poster Detailing GTX-104 STRIVE-ON Trial

Shares of KeyCorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/key#NYSE">KEY</a>) moved lower during Thursday&rsquo;s session after the company reported fourth-quarter financial results.
Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the consensus of $1.532 billion. Adjusted EPS of 25 cents topped the street view of 23 cents.
KeyCorp shares fell 5.4% to $13.10 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyt#NASDAQ">LYT</a>) shares jumped 92.8% to $0.1824 after falling 5% on Wednesday.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) shares jumped 90% to $2.2401. Agrify said it entered into first Hydrocarbon Extraction Lab &amp; Vertical Farming unit facility in California.</li>
<li>Phunware, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phun#NASDAQ">PHUN</a>) shares jumped 67.9% to $0.2730. Phunware shares dipped 61% on Wednesday after the company announced pricing of a $7 million registered direct offering price at-the-market under Nasdaq rules.</li>
<li>Celularity Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celu#NASDAQ">CELU</a>) shares surged 43.4% to $0.2705 after falling more than 5% on Wednesday.</li>
<li>Marpai, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrai#NASDAQ">MRAI</a>) shares jumped 34.4% to $1.1359 after declining over 8% on Wednesday. Marpai recently named John Powers as President.</li>
<li>Akoustis Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akts#NASDAQ">AKTS</a>) gained 21.7% to $0.7698.</li>
<li>Baijiayun Group Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rtc#NASDAQ">RTC</a>) gained 18.8% to $3.73.</li>
<li>M.D.C. Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdc#NYSE">MDC</a>) rose 18.2% to $62.76 after the company announced it will be acquired by Sekisui House.</li>
<li>CURO Group Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/curo#NYSE">CURO</a>) gained 15.7% to $0.8499.</li>
<li>Lexeo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxeo#NASDAQ">LXEO</a>) rose 13% to $19.58.</li>
<li>Aurora Technology Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atak#NASDAQ">ATAK</a>) gained 13% to $4.79.</li>
<li>Acasti Pharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acst#NASDAQ">ACST</a>) jumped 12.4% to $2.45.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) gained 11.8% to $1.6750. Dada Nexus recently announced that it discovered suspicious practices in an internal audit.</li>
<li>Cadrenal Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvkd#NASDAQ">CVKD</a>) surged 11.8% to $0.9499 after gaining over 7% on Wednesday.</li>
<li>Lanvin Group Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lanv#NYSE">LANV</a>) jumped 9.3% to $2.5901.</li>
<li>LiveRamp Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ramp#NYSE">RAMP</a>) gained 9.2% to $40.30. LiveRamp Holdings said it sees preliminary third-quarter revenue of $174 million and announced plans to acquire Habu.</li>
<li>Roma Green Finance Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) surged 8.8% to $1.24 after tumbling over 70% on Wednesday.</li>
<li>Taiwan Semiconductor Manufacturing Company Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>) gained 8.1% to $111.26 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/htz#NASDAQ">HTZ</a>) gained 7.1% to $8.95 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight but cut its price target form $16 to $15.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aravive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arav#NASDAQ">ARAV</a>) shares dipped 50.9% to $0.0542. Aravive intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcsa#NASDAQ">PCSA</a>) fell 28.7% to $0.1975. Processa Pharmaceuticals said it will effect a 1-for-20 reverse stock split.</li>
<li>Newcourt Acquisition Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncac#NASDAQ">NCAC</a>) shares fell 27.3% to $8.43 after gaining around 12% on Wednesday.</li>
<li>Cano Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cano#NYSE">CANO</a>) dipped 26.4% to $1.76.</li>
<li>eHealth, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ehth#NASDAQ">EHTH</a>) fell 23.3% to $5.36. Craig-Hallum analyst George Sutton downgraded eHealth from Buy to Hold.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zvsa#NASDAQ">ZVSA</a>) declined 23% to $0.53. ZyVersa Therapeutics recently announced the publication of an article in the peer-reviewed journal Acta Neuropathologica Communications, demonstrating that inflammasome activation enhances cancer metastasis to the brain in women with triple-negative breast cancer (TNBC).</li>
<li>ProQR Therapeutics N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prqr#NASDAQ">PRQR</a>) fell 20.4% to $2.2678.</li>
<li>Li-Cycle Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/licy#NYSE">LICY</a>) declined 18.5% to $0.4251.</li>
<li>LuxUrban Hotels Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/luxh#NASDAQ">LUXH</a>) fell 18% to $3.5430. LuxUrban responded to allegations in short seller report, highlighting mischaracterizations and speculation.</li>
<li>Nuvve Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvve#NASDAQ">NVVE</a>) shares fell 18.2% to $0.0830. Nuvve Holding will effect 1-for-40 reverse stock split, to be effective Jan. 19, 2024.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zcar#NASDAQ">ZCAR</a>) fell 16.8% to $4.25. Zoomcar recently appointed Adarsh Menon as President.</li>
<li>QuantaSing Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qsg#NASDAQ">QSG</a>) declined 16.4% to $2.5410. QuantaSing said it launched private label Chinese Baijiu brand YUNTING.</li>
<li>Cutera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cutr#NASDAQ">CUTR</a>) fell 16% to $3.0601. Cutera recently reported preliminary FY23 revenue guidance above prior estimates.</li>
<li>Airspan Networks Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mimo#NASDAQ">MIMO</a>) shares declined 13.5% to $0.1900. Airspan shares jumped 186% on Wednesday after the company announced a partnership with GCT Semiconductor to develop an RF module.</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) fell 12.2% to $5.39 on continued downward momentum after a federal judge blocked JetBlue Airways from acquiring the company. Citigroup analyst Stephen Trent downgraded Spirit Airlines from Neutral to Sell and lowered the price target from $13 to $4.</li>
<li>Plug Power Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plug#NASDAQ">PLUG</a>) shares dipped 12.1% to $2.4050 after the company announced it entered into an at market issuance sales agreement with B. Riley Securities for a common stock offering of up to $1 billion.</li>
<li>Meta Materials Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mmat#NASDAQ">MMAT</a>) shares declined 11.8% to $0.0673 after gaining 5% on Wednesday.</li>
<li>Humana Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hum#NYSE">HUM</a>) fell 11.5% to $396.49 after the company issued soft 2023 adjusted EPS guidance.</li>
<li>Fortuna Silver Mines Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsm#NYSE">FSM</a>) declined 11.2% to $3.14. Fortuna Silver Mines said fourth-quarter gold equivalent production rose 6% sequentially, while silver production fell 19% quarter-over-quarter.</li>
<li>Sify Technologies Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sify#NASDAQ">SIFY</a>) dipped 10.8% to $1.56 after the company reported worse-than-expected third-quarter sales results.</li>
<li>Nukkleus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nukk#NASDAQ">NUKK</a>) fell 9.4% to $1.2510 after falling 6% on Wednesday. Nukkleus announced its intention to expand its investment in Jacobi Asset Management, known for sponsoring Europe&rsquo;s first approved Bitcoin spot ETF.</li>
<li>Mersana Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrsn#NASDAQ">MRSN</a>) dipped 8.3% to $2.65.</li>
<li>Discover Financial Services (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dfs#NYSE">DFS</a>) fell 6.9% to $101.22 after the company reported a 62% plunge in its profit for the fourth quarter on Wednesday.</li>
<li>U.S. Bancorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usb#NYSE">USB</a>) slipped 3.7% to $39.31.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36673023/jim-cramer-says-buy-this-utilities-stock-down-6-over-past-6-months-calls-bunge-a-battleg"> Jim Cramer Says Buy This Utilities Stock Down 6% Over Past 6 Months, Calls Bunge A &#39;Battleground&#39;</a>

Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Acasti Announces Dosing Of First Patient In GTX-104 STRIVE-ON Trial

Offerings

Acasti Pharma Inc Files For Shelf Of Up To 6.6M Common Shares By Selling Stockholders

Insider Trades

Acasti Pharma 10% Owner Vimal  Kavuru Reported Purchase Of 1,099,103 Shares @ Avg Price: Of $1.19/Share In Form 4 Filing On Wednesday

<h3>Gainers</h3>
<ul>
<li>Soleno Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slno#NASDAQ">SLNO</a>) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome.</li>
<li>Femasys Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/femy#NASDAQ">FEMY</a>) surged 244% to $1.1410 after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman&#39;s fallopian tube.</li>
<li>Intercept Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icpt#NASDAQ">ICPT</a>) shares gained 77.3% to $18.50. Alfasigma agreed to acquire Intercept Pharmaceuticals for $19.00 per share in cash.</li>
<li>Immunovant, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imvt#NASDAQ">IMVT</a>) jumped 75.6% to $35.60 after the company announced initial IMVT-1402 Phase 1 SAD and 300 mg subcutaneous MAD results.</li>
<li>Tharimmune Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thar#NASDAQ">THAR</a>) shares gained 39.5% to $0.3090 after falling around 5% on Monday.</li>
<li>Acasti Pharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acst#NASDAQ">ACST</a>) gained 27.1% to $2.2250. Acasti announced a $7.5 million private placement equity financing.</li>
<li>Cano Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cano#NYSE">CANO</a>) surged 24.2% to $0.3380. Cano Health said it sold substantially all of the assets associated with the operation of Cano Health&#39;s senior-focused primary care centers in Texas and Nevada to CenterWell Senior Primary Care.</li>
<li>Bullfrog AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfrg#NASDAQ">BFRG</a>) gained 23.6% to $3.5499. Bullfrog AI announced data from its preclinical study investigating the anti-cancer activity of a novel prodrug of mebendazole for glioblastoma.</li>
<li>Avalo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avtx#NASDAQ">AVTX</a>) gained 21.9% to $0.1987 after jumping over 36% on Monday. Avalo Therapeutics reported the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adpt#NASDAQ">ADPT</a>) shares climbed 21.2% to $6.16. Adaptive recently announced the launch of Epic integration for clonoSEQ.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) shares gained 19.7% to $0.1561. Infobird recently announced receipt of delinquency notification letter from the Nasdaq.</li>
<li>ARS Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spry#NASDAQ">SPRY</a>) gained 18.8% to $4.28 after Director Rajeev Shah acquired a total of 2,700,000 shares an average price of $3.03 for roughly $8.18 million.</li>
<li>Roivant Sciences Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roiv#NASDAQ">ROIV</a>) gained 17% to $11.94 after the company announced initial IMVT-1402 Phase 1 SAD and 300 mg subcutaneous MAD results.</li>
<li>Verve Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verv#NASDAQ">VERV</a>) rose 16.6% to $13.25. Verve Therapeutics to unveil interim data on VERVE-101 at the American Heart Association&#39;s Event.</li>
<li>Pliant Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plrx#NASDAQ">PLRX</a>) gained 15% to $16.77 after the company announced bexotegrast met its primary and secondary endpoints in the Phase 2a liver fibrosis trial.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) rose 14.2% to $6.06 after the company announced that deliveries are set to ramp up.</li>
<li>Planet Green Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/plag#NYSE">PLAG</a>) surged 14.1% to $0.6470.</li>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) rose 13.2% to $1.01.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adpt#NASDAQ">ADPT</a>) gained 12.4% to $5.71.</li>
<li>Acutus Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afib#NASDAQ">AFIB</a>) jumped 11.7% to $0.6601.</li>
<li>Aclarion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acon#NASDAQ">ACON</a>) gained 11.4% to $0.39.</li>
<li>Vera Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vera#NASDAQ">VERA</a>) climbed 10.3% to $15.69 as HC Wainwright &amp; Co maintained a Buy rating on the stock and raised its price target from $10 to $25.</li>
<li>Blue Star Foods Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bsfc#NASDAQ">BSFC</a>) rose 8.6% to $0.2520 after dipping 20% on Monday.</li>
<li>NightHawk Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nhwk#NASDAQ">NHWK</a>) gained 7.5% to $0.57.</li>
<li>Precigen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgen#NASDAQ">PGEN</a>) rose 7.4% to $1.44.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) shares fell 68.7% to $0.7990 after the company priced its $8 million public offering of 15.7 million shares at $0.51 per share.</li>
<li>Murphy Canyon Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdt#NASDAQ">CDT</a>) fell 35.7% to $6.67 after dipping 38% on Monday.</li>
<li>Davis Commodities Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtck#NASDAQ">DTCK</a>) declined 33.2% to $3.15. The company recently priced its IPO at $4 per share.</li>
<li>Molekule Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mkul#NASDAQ">MKUL</a>) fell 28.8% to $0.2064.</li>
<li>Polished.com Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pol#NYSE">POL</a>) fell 25.2% to $0.0928 after surging 40% on Monday.</li>
<li>United Natural Foods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unfi#NYSE">UNFI</a>) fell 23.3% to $14.51 after the company reported mixed fourth-quarter financial results and issued guidance.</li>
<li>MicroAlgo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlgo#NASDAQ">MLGO</a>) fell 19.2% to $2.43.</li>
<li>Genetron Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gth#NASDAQ">GTH</a>) fell 18.2% to $0.7201.</li>
<li>Greenfire Resources Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gfr#NYSE">GFR</a>) declined 16.4% to $6.52.</li>
<li>Novo Integrated Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvos#NASDAQ">NVOS</a>) fell 14.9% to $0.2261.</li>
<li>Ebix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ebix#NASDAQ">EBIX</a>) dipped 12.8% to $10.36.</li>
<li>New Pacific Metals Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/newp#NYSE">NEWP</a>) declined 12.2% to $1.9487. New Pacific Metals announced CAD$35 million bought deal financing.</li>
<li>Greenfire Resources Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gfr#NYSE">GFR</a>) fell 11.5% to $6.90.</li>
<li>Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) fell 11.2% to $1.4099. Biophytis shares jumped over 72% on Monday after the company and Skyepharma announced a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19.</li>
<li>Roadzen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdzn#NASDAQ">RDZN</a>) fell 10.3% to $4.8135.</li>
<li>Akili, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akli#NASDAQ">AKLI</a>) declined 9.4% to $0.5130.</li>
<li>FaZe Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faze#NASDAQ">FAZE</a>) shares fell 8.9% to $0.1749 after jumping 25% on Monday.</li>
<li>MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) shares fell 7.8% to $0.1867 after declining around 15% on Monday.</li>
<li>TROOPS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/troo#NASDAQ">TROO</a>) fell 6.4% to $3.8199.</li>
<li>Sacks Parente Golf, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spgc#NASDAQ">SPGC</a>) fell 6.3% to $1.2750. The company recently posted a narrower second-quarter loss.</li>
<li>TD SYNNEX Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snx#NYSE">SNX</a>) fell 5.2% to $96.64. TD Synnex reported a third-quarter revenue decline of 9.1% Y/Y to $13.96 billion, missing the consensus of $14.11 billion.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/09/34909189/ethereum-rises-but-remains-below-this-key-level-maker-emerges-as-top-gainer"> Ethereum Rises But Remains Below This Key Level; Maker Emerges As Top Gainer</a>

Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Acasti Pharma Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acst#NASDAQ">ACST</a>) shares are trading higher by 34.3% to $2.35 Tuesday morning after the company announced <a href="https://www.benzinga.com/pressreleases/23/09/g34901957/acasti-announces-7-5-million-private-placement-equity-financing">$7.5 million in private placement equity financing</a>.
Acasti Pharma says the gross proceeds to the company from the private placement were approximately&nbsp;$7.5 million, before deducting fees and expenses.
The company says it currently intends to use the net proceeds from the private placement for clinical trial expenses to further the Phase 3 clinical trial for GTX-104, the Acasti Pharma&#39;s lead product candidate, pre-commercial planning, working capital and other general corporate purposes.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ACST has a 52-week high of $5.05 and a 52-week low of $1.72.

WIIM

Acasti Pharma shares are trading higher after the company announced $7.5 million in private placement equity financing.

Acasti Announces $7.5M Private Placement Equity Financing

Acasti Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACST#NASDAQ">ACST</a>) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104 its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that a poster presenting a pharmacokinetic comparison of GTX-104 with oral nimodipine has been accepted for presentation at the 2023 Neurocritical Care Society (NCS) annual meeting, to be held in Phoenix, AZ August 15-18, 2023. &nbsp;
Details of the presentation are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>GTX-104, Novel IV Formulation of Nimodipine to Treat Subarachnoid Hemorrhage: a Pharmacokinetic Comparison with Oral Nimodipine</td>
</tr>
<tr>
<td>Poster Number:</td>
<td>247</td>
</tr>
<tr>
<td>Author:</td>
<td>Amresh Kumar, Vice President of Program Management for Acasti</td>
</tr>
<tr>
<td>Date:</td>
<td>Wednesday August 16, 2023</td>
</tr>
<tr>
<td>Time:</td>
<td>4:00 – 5:00 PM</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
About aneurysmal Subarachnoid Hemorrhage (aSAH)
aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm. Approximately 70% of aSAH patients experience death or dependence, and more than 30% die within one month of hemorrhage. Approximately 50,000 patients in the United States are affected by aSAH per year, based on market research.
About GTX-104
GTX-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for intravenous infusion (IV) in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTX-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion.
GTX-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTX-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTX-104 has the potential to better manage hypotension in aSAH patients. GTX-104 has been administered in over 150 healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to oral nimodipine. The addressable market in the United States for GTX-104 is estimated to be about $300 million, based on market research.

Acasti To Present GTX-104 Pharmacokinetic Comparison Data At Neurocritical Care Annual Meeting

STRIVE-ON is a pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety and tolerability profile relative to oral nimodipine in patients hospitalized with aSAH

Acasti Announces WuXi Clinical As CRO To Conduct STRIVE-ON Phase 3 Safety Trial For GTX-104 In aSAH Patients

Acasti Pharma Inc. (&quot;Acasti&quot; or the &quot;Company&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACST#NASDAQ">ACST</a>), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company will effect a 1-for-6 reverse split of its issued and outstanding common shares. The reverse stock split will become effective&nbsp;July 10, 2023&nbsp;at&nbsp;12:01 a.m. ET. The Company&#39;s common shares will trade on a split-adjusted basis on The NASDAQ Capital Market, as of the opening of trading on&nbsp;Monday, July 10, 2023. The new CUSIP number for the Company&#39;s common shares will be 00430K865.
The reverse stock split is being affected as part of the Company&#39;s plan to regain compliance with the&nbsp;$1.00&nbsp;minimum bid price continued listing requirement of The NASDAQ Capital Market.
When the reverse stock split becomes effective, every six common shares of Acasti will be automatically combined into one new common share of Acasti. No fractional shares will be issued, and no cash or other consideration will be paid. Instead, the Company will issue one whole share of the post-split common shares to any stockholder of record who otherwise would have received a fractional share as a result of the reverse stock split.
The reverse stock split will reduce the number of outstanding common shares from approximately 44.6 million shares to approximately 7.4 million shares.
Acasti&#39;s transfer agent is Computershare Services Inc. Stockholders holding paper certificates representing pre-split holdings can contact our transfer agent by calling (800) 564-6253 (Canada&nbsp;and U.S.), (514) 982-7555 (Outside North America), or by email directed to&nbsp;<a href="mailto:corporateactions@computershare.com">corporateactions@computershare.com</a>&nbsp;for the procedure to exchange existing stock certificates for new stock certificates or book-entry shares. Certificates representing pre-split holdings will be deemed to represent the stockholder&#39;s past split holdings until the stockholder presents the certificate to the transfer agent. Stockholders who are holding their shares in electronic form or through a brokerage facility do not have to take any action as the effects of the reverse stock split will automatically be reflected in their brokerage accounts.

Stock Split

Acasti Pharma Announces 1-For-6 Reverse Stock Split

<h3>Gainers</h3>
<ul>
<li>Allarity Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allr#NASDAQ">ALLR</a>) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in DRP-selected metastatic breast cancer patients.</li>
<li>iMedia Brands, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imbi#NASDAQ">IMBI</a>) shares climbed 85.7% to $0.2201 after dropping 10% on Monday. iMedia Brands recently announced receipt of second Nasdaq non-compliance notice.</li>
<li>LightPath Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lpth#NASDAQ">LPTH</a>) rose 30% to $1.75.</li>
<li>Impel Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/impl#NASDAQ">IMPL</a>) shares gained 26% to $1.6001 after the company received US patent for respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for Parkinson&#39;s disease</li>
<li>GameSquare Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/game#NASDAQ">GAME</a>) gained 23.7% to $3.66. Dairy MAX and Gaming Community Network, a GameSquare Holdings&#39; company, announced the &quot;Level Unlocked Tournament.&quot;</li>
<li>TMC the metals company Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmc#NASDAQ">TMC</a>) rose 21% to $2.36. On June 30, the company received written notice from Nasdaq notifying that it has regained compliance with minimum bid requirement.</li>
<li>BioXcel Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btai#NASDAQ">BTAI</a>) shares climbed 19% to $9.40.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ino#NASDAQ">INO</a>) gained 18.3% to $0.5169.</li>
<li>Spark Networks SE (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lov#NASDAQ">LOV</a>) gained 17.7% to $0.4534.</li>
<li>C4 Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cccc#NASDAQ">CCCC</a>) shares gained 17% to $3.3099 after the company announced the FDA cleared its investigational new drug application for CFT8919.</li>
<li>Pegasystems Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pega#NASDAQ">PEGA</a>) gained 14% to $55.87. Wedbush upgraded Pegasystems from Neutral to Outperform.</li>
<li>Acasti Pharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acst#NASDAQ">ACST</a>) rose 13.9% to $0.5946. Acasti announced alignment with the FDA on GTX-104 pivotal Phase 3 safety trial protocol and confirmed planned initiation of STRIVE-ON in aSAH patients in calendar fourth quarter.</li>
<li>Wolfspeed, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wolf#NYSE">WOLF</a>) gained 12.7% to $63.97 after the company announced a 10-year silicon carbide wafer supply deal with Renesas Electronics Corporation.</li>
<li>Mullen Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/muln#NASDAQ">MULN</a>) gained 12.5% to $0.1135. The company announced the retention of Chistian Attar to combat naked short selling activities Wednesday morning.</li>
<li>Digital World Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dwac#NASDAQ">DWAC</a>) rose 10% to $13.92. New reports indicate the company reached a settlement with the U.S. Securities and Exchange Commission (SEC).</li>
<li>Xos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xos#NASDAQ">XOS</a>) rose 9.5% to $0.2416.</li>
<li>Opera Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opra#NASDAQ">OPRA</a>) gained 9.2% to $23.48.</li>
<li>XPeng Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpev#NYSE">XPEV</a>) climbed 8.3% to $15.15. Xpeng sees sharp growth in deliveries during the second half of the year.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>1847 Holdings LLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/efsh#NYSE">EFSH</a>) fell 31.3% to $0.2406 after the company reported pricing of $1.869 million public offering.</li>
<li>Fresh Vine Wine, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vine#NYSE">VINE</a>) fell 29.9% to $0.4067 after jumping around 157% on Monday.</li>
<li>Longevity Market Assets LLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abl#NASDAQ">ABL</a>) shares dipped 23.7% to $8.27 after starting trading on the Nasdaq.</li>
<li>Canopy Growth Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) shares fell 19.4% to $0.4737. Canopy Growth shares gained 52% on Monday after the company announced it completed all conversions pursuant to the $100 million convertible debentures and provided an update to its balance sheet actions taken to date.</li>
<li>Gaucho Group Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vino#NASDAQ">VINO</a>) dropped 16.6% to $0.5499.</li>
<li>Arrival (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arvl#NASDAQ">ARVL</a>) fell 15.8% to $2.33. Arrival said on Monday that its proposed merger with special purpose acquisition company Kensington Capital Acquisition Corp V has been terminated.</li>
<li>Pioneer Power Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ppsi#NASDAQ">PPSI</a>) dropped 15.3% to $8.30.</li>
<li>Amneal Pharmaceuticals, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amrx#NYSE">AMRX</a>) fell 14.7% to $2.60 after the company received FDA complete response letter for its IPX203 new drug application for Parkinson&#39;s disease.</li>
<li>AXT, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axti#NASDAQ">AXTI</a>) fell 14.5% to $3.00. AXT said Tongmei, its subsidiary in China, expects to proceed to immediately seek permits from the applicable Chinese authorities to export gallium and germanium substrate products.</li>
<li>IMAC Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/back#NASDAQ">BACK</a>) fell 14.3% to $0.1191 after jumping 26% on Monday. Theralink Technologies and IMAC Holdings recently entered into a merger agreement.</li>
<li>Nocera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncra#NASDAQ">NCRA</a>) declined 13.9% to $2.36.</li>
<li>MicroCloud Hologram Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holo#NASDAQ">HOLO</a>) dropped 13.9% to $2.9528.</li>
<li>Biofrontera Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfri#NASDAQ">BFRI</a>) fell 13.7% to $9.30. Benchmark maintained Biofrontera with a Buy and lowered the price target from $140 to $18.</li>
<li>Cassava Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sava#NASDAQ">SAVA</a>) dropped 12.1% to $22.26. The company announced the top-line clinical results from its Cognition Maintenance Study where oral simufilam in patients with mild-to-moderate Alzheimer&#39;s slowed cognitive decline.</li>
<li>22nd Century Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NASDAQ">XXII</a>) fell 12% to $3.9350. 22nd Century shares dropped 22% on Monday after the company announced a 1-for-15 reverse stock split.</li>
<li>Zuora, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zuo#NYSE">ZUO</a>) dropped 11.9% to $9.84.</li>
<li>Biotricity, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btcy#NASDAQ">BTCY</a>) dipped 11.7% to $2.85. HC Wainwright &amp; Co. reiterated Biotricity with a Buy and raised the price target from $2 to $4.</li>
<li>Osisko Gold Royalties Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/or#NYSE">OR</a>) fell 11.2% to $13.97.</li>
<li>Wabash National Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wnc#NYSE">WNC</a>) dropped 10.8% to $23.15 after Raymond James downgraded the stock from Strong Buy to Market Perform.</li>
<li>Advanced Health Intelligence Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahi#NASDAQ">AHI</a>) fell 10% to $5.13. Bank of New York Mellon raised stake in Advanced Health Intelligence from 21.08% to 22.52%.</li>
<li>Puyi Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/puyi#NASDAQ">PUYI</a>) fell 9.6% to $6.02.</li>
<li>Alliance Entertainment Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aent#NASDAQ">AENT</a>) fell 9.4% to $2.50. Alliance Entertainment recently reported pricing of public offering and Nasdaq listing.</li>
<li>Accolade, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/accd#NASDAQ">ACCD</a>) fell 9.3% to $11.96.</li>
<li>Amyris, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amrs#NASDAQ">AMRS</a>) declined 8.5% to $1.07.</li>
<li>Butterfly Network, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NYSE">BFLY</a>) dropped 8.3% to $2.1750.</li>
<li>GeoPark Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gprk#NASDAQ">GPRK</a>) fell 8.2% to $9.05.</li>
<li>Compass, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/comp#NYSE">COMP</a>) declined 7.2% to $3.4150.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/07/33116328/bitcoin-drops-but-remains-above-30-000-compound-becomes-top-loser"> Bitcoin Drops But Remains Above $30,000; Compound Becomes Top Loser</a>

ACCD

AENT

ALLR

AMRS

AMRX

ARVL

AXTI

BACK

BFLY

BFRI

BTAI

BTCY

CCCC

COMP

DWAC

EFSH

GAME

GPRK

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IMBI

IMPL

LPTH

MULN

NCRA

OPRA

PEGA

PPSI

PUYI

SAVA

VINE

VINO

WOLF

XPEV

XXII

Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Acasti Announces Alignment With FDA On GTX-104 Pivotal Phase 3 Safety Trial Protocol And Confirms Planned Initiation Of STRIVE-ON In aSAH Patients In Calendar Q4 2023

Acasti Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACST#NASDAQ">ACST</a>) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 175 percent decrease over losses of $(0.04) per share from the same period last year.

UPDATE: Acasti Pharma Q4 Adj EPS $(0.11), Inline

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Novavax (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvax-stock-quote/">NVAX</a>) stock was among the laggards in the race for the vaccine against COVID-19. Unsurprisingly, NVAX stock plunged from highs of $320 in 2021 to recent lows of $3.5.



However, with the company announcing a deal with Sanofi (NASDAQ:<a href="https://investorplace.com/stock-quotes/sny-stock-quote/">SNY</a>), the stock skyrocketed by 280% last month. With the likelihood of the return of the meme stock frenzy, it&rsquo;s a good time to look at <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> to buy for returns that can replicate the performance of NVAX stock.



Therefore, I am looking at speculative ideas for multibagger returns in the blink of an eye. The column does not discuss blue-chip or high-quality biotech stocks. The biotech stocks discussed represent companies with the possibility of positive news regarding drug pipeline outcomes.



The possibility of rate cuts in the second half of 2024 strengthens my conviction on a broad-based rally for speculative ideas. Easy money policies translate into higher trading activity across risky asset classes. Let&rsquo;s, therefore, discuss three biotech stocks to buy before they skyrocket.



<h2>Acasti Pharma (ACST)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/01/shutterstock_1392543755-min-300x169.jpg" alt="There's No Miraculous Comeback Looming for Acasti Pharma Stock"><div>Source: Pavel Kapysh / Shutterstock.com</div></div>Acasti Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/acst-stock-quote/">ACST</a>) is a micro-cap biotech stock that looks poised for a big rally after being sideways in the last 12 months. As an overview, Acasti is a clinical-stage company working on products for rare and orphan diseases in Canada.



The company&rsquo;s pipeline includes GTX-104, an injectable formulation of nimodipine being developed for intravenous infusion (IV) in aSAH patients. The other <a href="https://www.acasti.com/our-pipeline">molecular entities in the pipeline</a> include GTX-102, GTX-101 and GTX-201.



However, GTX-104 is in the third stage of clinical trials and is a potential catalyst for ACST stock upside. It&rsquo;s worth noting that Acasti plans to <a href="https://www.acasti.com/investors/news-events/press-releases/detail/269/acasti-announces-third-fiscal-quarter-2024-financial-results-and-business-highlights">submit the new drug application</a> (NDA) for GTX-104 in the first half of 2025. This will be an important development, and I expect ACST stock to rally prior to the NDA submission.



Another important point is that the company secured a $7.5 million private placement last quarter. With this, the cash runway extends into Q2 2026.



<h2>Entera Bio (ENTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/medical-tools-tech-therapeutics-300x169.png" alt="An image of a tablet with 'therapeutics' on the screen, a stethoscope and face mask around it"><div>Source: ra2 studio/Shutterstock</div></div>It&rsquo;s worth noting that Entera Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/entx-stock-quote/">ENTX</a>) has skyrocketed by almost 300% year-to-date. However, a market valuation of $85 million indicates a headroom for further upside, with clinical trials delivering encouraging results.



As an overview, Entera Bio focuses on developing and commercializing orally delivered peptide and protein therapeutics.



The company has five clinical programs with EB613 (for osteoporosis) set to enter phase three trials. It&rsquo;s worth noting that 200 million women globally have osteoporosis. Further, more than one billion women will enter menopause in the coming years.



This presents a <a href="https://investors.enterabio.com/static-files/4693db2f-a010-42ec-9b1c-018f378ea159">big opportunity for EB613</a>, with no new osteoporosis therapy being approved since 2019. It&rsquo;s, therefore, not surprising the ENTX stock is surging higher as clinical trials are set to enter the critical third stage. Bone mineral density (BMD) endpoint qualification for EB613 is expected by January 2025. That&rsquo;s a potential catalyst for a sustained rally in ENTX stock.



<h2>Karyopharm Therapeutics (KPTI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>Karyopharm Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kpti-stock-quote/">KPTI</a>) is a commercial-stage biotech company. KPTI stock has been in a correction mode with a downside of 55% in the last 12 months. However, the selling is overdone and the stock is poised for a big rally.



It&rsquo;s worth noting that the company&rsquo;s commercialized candidates, XPOVIO and NEXPOVIO, have <a href="https://investors.karyopharm.com/events-presentations">approvals in 40 countries</a>.



Further, the last-stage pipeline (SELINEXOR) comprises candidates for endometrial cancer, multiple myeloma and myelofibrosis. With the <a href="https://www.karyopharm.com/science/pipeline/">current late-stage pipeline</a>, the company expects a $2 billion peak revenue potential in the United States.



Earlier this month, $148 million of <a href="https://investors.karyopharm.com/2024-05-08-Karyopharm-Announces-Significant-Refinancing-Transactions-and-Amended-Royalty-Agreement-Extending-Vast-Majority-of-Its-Debt-Maturities-into-2028-and-2029">existing convertible notes</a> due in 2025 were extended to 2029. The company also issued a $100 million senior secured term loan due 2028. With refinancing, Karyopharm Therapeutics is better positioned from a financial perspective.



For 2024, the company has <a href="https://investors.karyopharm.com/2024-05-08-Karyopharm-Reports-First-Quarter-2024-Financial-Results-and-Highlights-Recent-Company-Progress">guided for revenue</a> of $140 to $160 million. U.S. XPOVIO net product revenue is expected at $100 to $120 million. With approval in multiple countries, there is headroom for healthy revenue growth in the coming years.



On the date of publication, Faisal Humayun did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Faisal Humayun is a senior research analyst with 12 years of industry experience in the field of credit research, equity research and financial modeling. Faisal has authored over 1,500 stock specific articles with focus on the technology, energy and commodities sector.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/the-next-novavax-3-biopharma-stocks-to-buy-before-they-boom/">The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
As the main stock indices like the S&amp;P 500 and Nasdaq continue to climb, <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuations and high risk, they offer the potential for impressive gains, especially in a bull market. For May, there are seven penny stocks worth considering. These companies, despite their low market capitalization and liquidity, have solid foundations and promising growth prospects, potentially minting new millionaires. This led to my list of strong buy penny stocks.



The Russell 2000 <a href="https://www.fxstreet.com/news/russell-2000-index-elliott-wave-technical-analysis-video-202406100741">Elliott Wave analysis</a> suggests we are in a trending market, favoring small-cap companies. While many penny stocks can be highly unpredictable and often fail, some under $1 stocks present a unique opportunity for those who understand the risks involved. These companies have the potential to achieve remarkable growth, making them worthy of consideration for any investor&rsquo;s portfolio.



So, here are three of the best strong buy penny stocks for investors to buy this month.



<h2>Tonix Pharmaceuticals (TNXP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnxp-stock-quote/">TNXP</a>) is a biopharmaceutical company that develops and commercializes therapeutics to treat and prevent human diseases. The company&rsquo;s portfolio includes treatments for central nervous system disorders, rare diseases, immunology and infectious diseases.



TNXP is <a href="https://www.tonixpharma.com/therapeutic-areas-overview/">actively pursuing</a> several key initiatives for 2024. The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL, targeting the management of fibromyalgia.



This decision follows positive outcomes from two Phase 3 trials, indicating significant improvements in sleep quality and pain reduction for fibromyalgia patients. The drug demonstrated a statistically significant improvement in sleep quality and daily pain reduction, making it a promising candidate for FDA approval&#8203;.



Analyst ratings for TNXP currently suggest a <a href="https://stockanalysis.com/stocks/tnxp/forecast/">Strong Buy</a> consensus, with an average price target indicating a potential upside of approximately 391% from its current trading levels. This optimism comes from the upcoming NDA submission and the potential market exclusivity of its drugs in key markets.



<h2>Mind Medicine (MNMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-300x169.jpg" alt="MNMD stock: A scientist holding a test tube in a stock image. AI Recommended Biotech Stocks"><div>Source: Shutterstock</div></div>Mind Medicine (NASDAQ:<a href="https://investorplace.com/stock-quotes/mnmd-stock-quote/">MNMD</a>) aims to be a leader in developing treatments for brain health disorders. The company is advancing a range of innovative drug candidates.



MNMD is <a href="https://ir.mindmed.co/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder">advancing its pipeline</a> with significant milestones planned for 2024. The company expects to initiate a Phase 3 clinical program for its lead candidate, MM120, in the second half of 2024, following an End-of-Phase 2 meeting with the FDA in the first half of the year.&nbsp;



The drug is being developed for the treatment of generalized anxiety disorder (GAD) and showed promising results in Phase 2b trials, including a 7.7-point improvement over placebo in anxiety symptoms at week 12.



The company also has <a href="https://www.businesswire.com/news/home/20240108449557/en/MindMed-Announces-Business-Update-and-Anticipated-Milestones-for-2024">several clinical trials in progress.</a> These include a Phase 1 trial for MM-402, a novel MDMA derivative, for autism spectrum disorder, and a Phase 2a trial for lysergide in treating anxiety disorders. The company&rsquo;s broad pipeline focuses on brain health disorders, with products targeting the serotonin, dopamine and acetylcholine systems&#8203;.



<h2>Acasti Pharma (ACST)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/01/shutterstock_1392543755-min-300x169.jpg" alt="There's No Miraculous Comeback Looming for Acasti Pharma Stock"><div>Source: Pavel Kapysh / Shutterstock.com</div></div>Acasti Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/acst-stock-quote/">ACST</a>) is a late-stage biopharma company focusing on developing and commercializing innovative treatments for rare and orphan diseases. The company is currently advancing its lead candidate, GTX-104, a novel injectable formulation of nimodipine for intravenous infusion, aimed at treating aneurysmal subarachnoid hemorrhage (aSAH).&nbsp;



For 2024, Acasti <a href="https://www.acasti.com/investors/news-events/press-releases/detail/261/acasti-announces-first-quarter-2024-financial-results-and-business-highlights">plans to submit a New Drug Application</a> (NDA) for GTX-104 to the FDA, based on data from ongoing and upcoming Phase 3 trials. Financially, the company reported a net loss of $4 million for Q1 2024, a slight improvement from the $4.5 million loss in Q1 2023. As of December 31, 2023, Acasti had $18.5 million in cash and equivalents, which it believes will fund operations into the second quarter of 2026.



Analyst ratings for ACST suggest a positive outlook, with a projected price target indicating a <a href="https://stockanalysis.com/stocks/acst/forecast/">potential significant upside</a> from current levels. This optimism comes from the anticipated NDA submission and the potential market impact of GTX-104.



On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Matthew Farley did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines.</a>
<div>Matthew started writing coverage of the financial markets during the crypto boom of 2017 and was also a team member of several fintech startups. He then started writing about Australian and U.S. equities for various publications. His work has appeared in MarketBeat, FXStreet, Cryptoslate, Seeking Alpha, and the New Scientist magazine, among others.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/wall-street-favorites-3-penny-stocks-with-strong-buy-ratings-for-june-2024/">Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024

Acasti Pharma GAAP EPS of -$1.35

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Acasti Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/acst-stock-quote/">ACST</a>) just reported results for the fourth quarter of 2024.<ul><li>Acasti Pharma reported earnings per share of -26 cents. This was above the analyst estimate for EPS of -35 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/acst-stock-earnings-acasti-pharma-for-q4-of-2024/">ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024

Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on Acasti Pharma (ACST – Research Report) today and set a price target of $6.00. T...

Craig-Hallum Sticks to Their Buy Rating for Acasti Pharma (ACST)

Oren Livnat, an analyst from H.C. Wainwright, reiterated the Buy rating on Acasti Pharma (ACST – Research Report). The associated price target is $...

Strong Buy: Acasti Pharma's GTX-104 Poised for Standard of Care in aSAH with Promising Market Outlook

Acasti Pharma GAAP EPS of -$0.24

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Acasti Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/acst-stock-quote/">ACST</a>) just reported results for the first quarter of 2025.<ul><li>Acasti Pharma reported earnings per share of -24 cents. This was above the analyst estimate for EPS of -25 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/acst-stock-earnings-acasti-pharma-for-q1-of-2025/">ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025

Craig-Hallum analyst Chase Knickerbocker assigned a Buy rating to the stock today. The company's shares closed yesterday at $2.39. Knickerbocker co...

Craig-Hallum Issues a Buy Rating on Acasti Pharma (ACST)

Acasti Pharma (ACST) just unveiled an announcement. Acasti Pharma Inc. has signed an employment agreement with Prashant Kohli as its CEO, offering ...

Acasti Pharma Appoints Prashant Kohli as CEO with Incentives

ENTX

KPTI

MNMD

NVAX

TNXP

Press Releases

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Health Care

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Acasti Pharma to Attend BIO International Convention 2024

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Acasti to Present at the Life Sciences Investor Forum

Craig-Hallum

EF Hutton

HC Wainwright & Co.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Acasti Pharma

Acasti Pharma (ACST) Forecast

Acasti Pharma (NASDAQ:ACST) Stock, Quote.Headers.trade-ideas